@article{ref1,
title="Cost analysis of osteoporosis related to untreated menopause",
journal="Clinical rheumatology",
year="1989",
author="Levy, E.",
volume="8 Suppl 2",
number="",
pages="76-82",
abstract="Menopausal osteoporosis has many consequences for women over 50. Its complications incur high treatment costs both for society and the patients themselves. Collection of the epidemiological data required for a cost analysis of menopause-related osteoporosis is not easy, but we have calculated the direct (i.e. purely medical) costs as follows: hip fractures: approximate number per annum in women over 50: 55,000, minimum hospital costs (treatment and rehabilitation): 3.5 bn FF; forearm fractures: approximate number per annum: 35,000, cost of out-patient treatment: 200 m FF; vertebral fractures: common, but generally unrecorded: estimated number 40,000-65,000 cost: unevaluated. The relative benefit of hormone therapy versus nontreatment may be used to calculate the cost of osteoporosis due to non treated menopause. In France, where currently only 5% women over 50 are treated, this cost is 2.2 bn FF. If 50% of women were treated, the savings from hormone therapy (in terms of osteoporosis treatment costs) could be 1.2 bn FF, a figure which must be weighed against a cost analysis of oestrogen therapy.<p /><p>Language: en</p>",
language="en",
issn="0770-3198",
doi="",
url="http://dx.doi.org/"
}